Constantly condensing the truth

In September 2022, he joined Shanghai Lishan Biopharmaceutical Co., LTD., and in February 2025, he was the chief consultant of Kein Biopharmaceutical Co., LTD

Professor, Department of Medicine, Department of Molecular Pharmacology, Department of Genetics, and Department of Oncology, Albert Einstein College of Medicine. M.d., Mount Sinai School of Medicine in New York, a resident in internal medicine at Yale-New Haven Hospital, and a former postdoctoral fellow at Yale University and lecturer at the University of Chicago.

He has chaired and reviewed several National Institutes of Health (NIH), National Cancer Institute (NCI), and Department of Defense (DOD) research grants. He has served on the editorial board of several internationally renowned journals, and has published more than 200 papers and nearly 10,000 citations in top international journals such as Nature and Science.

The discovery of endogenous PXR ligands and the use of microbial metabolites to simulate the design of anti-intestinal inflammation and cancer drugs revealed new microorganisms and their mechanisms of regulating innate immunity, and made great contributions to the analysis of the pathological mechanisms of immune-related chronic diseases (such as inflammatory bowel disease, diabetes and cancer) and proposed new therapeutic approaches.